Table 2

Selected ongoing studies using checkpoint blockade immunotherapy in treatment of recurrent or metastatic cervical cancer

NCT identifierTitlePhasePlanned enrollmentPrimary endpoint(s)
NCT03257267Study of Cemiplimab in Adults With Cervical CancerIII590Overall survival
NCT03912415Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)III316Overall survival
NCT03556839Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc)III404Overall survival
NCT03192059Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO)II43Objective response rate
NCT03614949SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerII26Overall response rate
NCT01693783Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerII44Adverse events, objective response rate
NCT03277482Durvalumab, Tremelimumab+Radiotherapy in Gynecologic CancerI32Maximum tolerated dose
NCT03452332Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersI20Adverse events